Antiviral monoclonal antibody cocktails as a modern weapon in combating pandemics

Therapeutic DeliveryVol. 13, No. 2 EditorialAntiviral monoclonal antibody cocktails as a modern weapon in combating pandemicsDingjiang Liu & Mohammed ShameemDingjiang LiuFormulations Development & Delivery Technology, Preclinical Development, Regeneron Pharmaceuticals, Inc., 777 Saw Mill River Road, Tarrytown, NY 10591–6707, USASearch for more papers by this author & Mohammed Shameem*Author for correspondence: E-mail Address: mohammed.shameem@regeneron.comFormulations Development & Delivery Technology, Preclinical Development, Regeneron Pharmaceuticals, Inc., 777 Saw Mill River Road, Tarrytown, NY 10591–6707, USASearch for more papers by this authorPublished Online:2 Nov 2021https://doi.org/10.4155/tde-2021-0079AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: antibody cocktailantiviralcoformulationformulationhigh concentrationmonoclonal antibodypandemicREGEN-COVSARS-CoV-2References1. Antibody Society, COVID-19 biologics tracker (2021). https://www.antibodysociety.org/covid-19-biologics-tracker/Google Scholar2. FDA. Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibody for Treatment of COVID-19 (2021). https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibody-treatment-covid-19Google Scholar3. Wang P, Nair M, Liu L et al. Antibody resistance of SARS-CoV-2 variants B. 1.351 and B. 1.1. 7. Nature 593(7857), 130–135 (2021).Crossref, Medline, CAS, Google Scholar4. Brennan Z. US to no longer distribute Eli Lilly’s bamlanivimab alone due to coronavirus variants (2021). https://endpts.com/us-to-no-longer-distribute-eli-lillys-bamlanivimab-alone-due-to-coronavirus-variants/Google Scholar5. FDA. Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19(2021). http://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19Google Scholar6. FDA. Fact Sheet For Health Care Providers Emergency Use Authorization (EUA) Of REGEN-COVTM (casirivimab and imdevimab)(2021). https://www.fda.gov/media/145611/downloadGoogle Scholar7. Sitlani A, Malhotra S, Aggarwal P et al. Monoclonal Antibodies For COVID-19 Are A Potentially Life-Saving Therapy: How Can We Make Them More Accessible? Health Affairs (2021). https://www.healthaffairs.org/do/10.1377/hblog20210901.667955/full/Google Scholar8. FDA. Fact Sheet For Healthcare Providers Emergency Use Authorization (EUA) Of Sotrovimab (2021). https://www.fda.gov/media/149534/downloadGoogle Scholar9. FDA. Fact Sheet For Health Care Providers Emergency Use Authorization (EUA) Of Bamlanivimab And Etesevimab (2021). https://www.fda.gov/media/145802/downloadGoogle Scholar10. Luo L, Jiang B, Cao Y et al. A hydrophobic interaction chromatography method suitable for quantitating individual monoclonal antibodies contained in co-formulated drug products. Journalof Pharmaceutical and Biomedical Analysis 193, 113703 (2021).Crossref, Medline, CAS, Google Scholar11. Chauhan V, Zhan H, Dalby P et al. Advancements in the co-formulation of biologic therapeutics. Journal of Controlled Release 327, 397–405(2020).Crossref, Medline, CAS, Google Scholar12. Rainwater-Lovett K, Redd J, Stewart M et al. Real-world Effect of Monoclonal Antibody Treatment in COVID-19 Patients in a Diverse Population in the United States. Open Forum Infectious Diseases 8(8), (2021). https://doi.org/10.1093/ofid/ofab398Crossref, Medline, Google ScholarFiguresReferencesRelatedDetails Vol. 13, No. 2 Follow us on social media for the latest updates Metrics Downloaded 60 times History Received 13 October 2021 Accepted 18 October 2021 Published online 2 November 2021 Published in print February 2022 Information© 2022 Newlands PressKeywordsantibody cocktailantiviralcoformulationformulationhigh concentrationmonoclonal antibodypandemicREGEN-COVSARS-CoV-2Financial & competing interests disclosureD Liu and M Shameem are employees of Regeneron Pharmaceuticals, Inc. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.M Shameem is a member of the Therapeutic Delivery Editorial Board. They were not involved in any editorial decisions related to the publication of this article.PDF download